Framework conditions facilitating paediatric clinical research
- PMID: 21345195
- PMCID: PMC3055809
- DOI: 10.1186/1824-7288-37-12
Framework conditions facilitating paediatric clinical research
Abstract
The use of unlicensed and "off-label" medicines in children is widespread. Between 50-80% of the medicines currently administered to children have neither been tested nor authorized for their use in the paediatric population which represents approximately 25% of the whole European population. On 26 January 2007, entered into force the European Regulation of Paediatric Medicines. It aims at the quality of research into medicines for children but without subjecting the paediatric population to unnecessary clinical trial. This article addresses ethical and legal issues arising from the regulation and makes recommendations for the framework conditions facilitating the development of clinical research with children.
References
-
- ERA-NET PRIOMEDCHILD. European Commission Sixth Framework Programme FP6 Project no. 036266. Coordination of research on priority medicines for children. http://www.priomedchild.eu/
-
- The European Parliament and the Council. Regulation on medicinal products for paediatric use and amending Regulation. http://eur-lex.europa.eu/LexUriServ/site/en/consleg/2006/R/02006R1901-20...
-
- Welzing L, Harnischmacher U, Weyersberg A, Roth B. Consequences of Directives 2001/20/EC for investigator-initiated trials in the paediatric population-a filed report. Eur J Pediatr. 2007;166:1169–1176. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
